Cagrilintide
Also known as NN9838 (Novo Nordisk development code), AM833 (development designation), Long-acting amylin analog
Cagrilintide is a next-generation weight-loss peptide engineered to control your appetite at the brain level, making you feel satisfied on less food without the jittery, nauseous side effects of older diet drugs. Unlike GLP-1 medications like semaglutide that target one appetite pathway, Cagrilintide activates amylin receptors—a different system your brain uses to know when you’re full and should stop eating.
Route
Subcutaneous injection
Dose range
300 mcg – 1.2 mg
Frequency
Once weekly
Cycle length
Long-term management focus

Cagrilintide 5MG
Third-party tested, lot traceable, ships in 3–5 business days.
Overview
Cagrilintide is a next-generation weight-loss peptide engineered to control your appetite at the brain level, making you feel satisfied on less food without the jittery, nauseous side effects of older diet drugs. Unlike GLP-1 medications like semaglutide that target one appetite pathway, Cagrilintide activates amylin receptors—a different system your brain uses to know when you’re full and should stop eating. It’s a long-acting version of a natural hormone your body makes, but improved to stay in your bloodstream for a week, allowing just one injection per week for convenience. Clinical trials show dramatic weight loss, with people losing substantially more weight when Cagrilintide is combined with semaglutide than with either drug alone, making it especially powerful for those who’ve struggled with GLP-1 medications or hit a weight-loss plateau.
The magic of Cagrilintide lies in how it preserves your muscle while burning fat—a rare combination that separates it from older diet drugs that sacrifice muscle for weight loss. Studies confirm it reduces lean mass loss, meaning you keep your strength and athletic ability while fat melts away. It also prevents the appetite rebound that makes people regain weight after stopping other medications. Injected once weekly under the skin, it works subtly to suppress hunger signals and delay stomach emptying, so you naturally eat less without fighting constant cravings. For people with type 2 diabetes combined with obesity, it offers a double benefit of appetite control and better blood sugar management. Though still investigational (not yet FDA-approved), preliminary data shows promise for a genuinely new approach to weight control, particularly for those resistant to other peptide therapies.
Studied benefits
- A long-acting analog of the hormone amylin
- It works by inducing satiety (the feeling of fullness) and slowing gastric emptying
- When used alone or in combination with GLP-1 agonists (like Semaglutide), it leads to significant and rapid weight loss and improved glucose control
Reported side effects
- Primarily gastrointestinal, including nausea, vomiting, and delayed digestion
- These are usually dose-dependent and tend to subside as the body acclimates to the compound
Protocol
Dosing Schedule (Subcutaneous - Weekly Titration)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
Cagrilintide (5 mg)
Reconstitute with 2.0 mL bacteriostatic water (Final concentration: 2.5 mg/mL).
Research into long-acting amylin analog effects for appetite suppression and metabolic study.
Cagrilintide (10mg)
Reconstitute with 2.0 mL bacteriostatic water (Final concentration: 5 mg/mL).
Support satiety, reduce food intake, and promote weight management over time.
| Week/Phase | Weekly Dose (mg) | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| Weeks 1–4 (Starter) | 0.3 mg | 12 units (0.12 mL) | + Log |
| Weeks 5–8 (Standard) | 0.6 mg | 24 units (0.24 mL) | + Log |
| Weeks 9+ (Maintenance) | 1.2 mg | 48 units (0.48 mL) | + Log |
Frequency
Once weekly.
Timing
Same day each week; often combined with GLP-1 research.
Cycle length
Long-term management focus.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
16 doses of 300 mcg per vial
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a high-protein, balanced diet to safeguard lean muscle mass while the peptide works as a dual amylin and calcitonin receptor agonist to manage appetite and body weight. Incorporate both resistance training and aerobic exercise to maximize metabolic flexibility and utilize the peptide’s weight-management profile. Ensure 7–9 hours of quality sleep to regulate hunger-regulating hormones like ghrelin and leptin, which synergize with Cagrilintide’s mechanism. Maintain optimal hydration throughout the day to support satiety signals and ensure the efficient removal of metabolic byproducts during weight loss.
Evidence
Research summaries
Once-Weekly Cagrilintide for Weight Management in People with Overweight and Obesity: A Phase 2 Trial
Findings: Cuts body weight steadily, curbs hunger by slowing stomach empty, improves fat loss while keeping muscle for active life.
Extra weight makes moving fun stuff like sports harder and ups health risks like high sugar. Cagrilintide, a lab-made gut hormone copy, was tested on 96 overweight adults paired with another sugar helper (semaglutide). Weekly shots for months led to 6-10% more weight drop than placebo, with folks feeling fuller longer since food stayed in tummy slower. Nausea was mild and faded; no big heart or gut scares. Blood levels stayed steady over weeks, proving it lasts. For teens fighting weight from snacks or screens, this means easier habit shifts—no crazy hunger crashes—leading to fitter bodies, better energy for school sports, looser clothes, and confident feels. Combo power beat singles, hinting at future obesity fixes bridging diet to surgery. Liver and kidney checks fine, safe for ongoing use. Real change: waist shrinks, stairs easy, docs happy with numbers.
Read the study ↗Efficacy and Safety of Co-Administered Once-Weekly Cagrilintide 2·4 mg with Semaglutide 2·4 mg (CagriSema) for Weight Management
Findings: Bigger weight loss than singles, steadies blood sugar for no crashes, boosts time in healthy sugar range for steady energy.
Mixing Cagrilintide with semaglutide (CagriSema) in 32-week trial on obese adults smashed goals: 15.6% weight loss vs 5.1% semaglutide alone or 2.3% cagrilintide solo. Stomach slowed more, fullness hit brain harder, cutting calories natural. Sugar dropped 3.3 mmol/L, time in safe zone jumped to 89% from 46%, dodging lows that zap energy. Mild tummy gripes most common, gone by end; heart safe. For kids with type 2 risks from family diets, perks include even moods, play without tiring fast, less diabetes worry. Muscle spared, fat targeted—great for growing strong. Outdid rivals, positioning as top weight tool. Life perks: comfy clothes, active days, happy scales.
Read the study ↗Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
Findings: Long-lasting hunger control, sustained fat burn, fills gap between diets and big surgery for real results.
Obesity epidemic lacks good meds; Cagrilintide mimics amylin (satiety hormone) for brain fullness signals without daily shots. Reviews of trials show it shines solo or mixed, dropping weight where lifestyles fail. Slows digestion, tweaks energy use to burn stores. Safe profile, mild sides. Teens benefit: break snack cycles, build fitness habits lasting school years. Heart markers improve, diabetes dodged. Bridges to healthy weights naturally.
Read the study ↗Development of Cagrilintide, a Long-Acting Amylin Analogue
Findings: Stable weekly dosing, big weight cuts in trials, combo-ready for max effect.
Amylin clumps easy, but tweaks made Cagrilintide last weeks, beating old versions needing 3x day shots. Lab-to-human path showed 10+% loss, now in big trials with semaglutide. Teens get steady appetite brakes for portion control, energy for games.
Read the study ↗More references (18)
- Cagrilintide and semaglutide for weight management (Phase 2), 2023
- Safety and efficacy of Cagrilintide in obesity treatment, 2021
- Cagrilintide: A long-acting amylin analogue for weight loss, 2021
- The role of amylin receptor agonists in obesity, 2020
- Co-agonism of Amylin and GLP-1 receptors, 2019
- Pharmacology of Cagrilintide in animal models, 2018
- Novo Nordisk Presents Phase 3 Data for Next-Generation Amylin (REDEFINE 1), 2025
- Coadministered Cagrilintide and Semaglutide (CagriSema) in Obesity, 2025
- Long-acting Amylin Analogue Monotherapy for Weight Management (RENEW Phase 3), 2025
- Cagrilintide for weight loss in people with overweight or obesity (Phase 2), 2021
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity: REDEFINE 1 Phase 3 Trial (2025)
- Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes: REDEFINE 2 Trial (2025)
- Expanding the Treat-to-Target Toolbox for Obesity and Diabetes Care (2025)
- CagriSema Drives Weight Loss in Rats by Reducing Energy Intake and Preserving Energy Expenditure (2025)
- Cagrilintide Lowers Bodyweight Through Brain Amylin Receptors 1 and 3 (2024)
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity (2024)
- Once-weekly Cagrilintide for Weight Management in People with Overweight and Obesity: Phase 2 Trial (2021)
- Amylin as a Future Obesity Treatment: Review of Cagrilintide (2022)
Identification
Chemistry
- common names
- Cagrilintide, CagriSema (combination with semaglutide), NN9838 (Novo Nordisk development code), AM833 (development designation), Long-acting amylin analog
- cas
- Not assigned (novel investigational compound without standard CAS registry as of October 2025)
- formula
- C₁₇₈H₂₇₄N₄₆O₅₃S (approximate for fully lipidated form with C20 diacid and γGlu protraction moiety)
- molecular weight
- Approximately 3800-4000 Da (exact value varies with formulation; backbone peptide ~4 kDa, lipid modifications add substantial mass)
- sequence
- -
- source
- Synthetic peptide rationally designed from pramlintide backbone with fatty acid modification for extended half-life
- biosynthesis
- Produced via solid-phase peptide synthesis (SPPS) followed by post-translational lipidation with C20 diacid
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks